We are live on ! Find out more
ELDN icon

Eledon Pharmaceuticals
ELDN

30 hedge funds and large institutions have $14.7M invested in Eledon Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

467% more call options, than puts

Call options by funds: $17K | Put options by funds: $3K

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

7% more funds holding

Funds holding: 28 → 30 (+2)

3% more capital invested

Capital invested by funds: $14.3M → $14.7M (+$389K)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

0.08% less ownership

Funds ownership: 45.43% → 45.35% (-0.08%)

Holders
30
Holders Change
+2
Holders Change %
+7.14%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
4
Reduced
4
Closed
5
Calls
$17K
Puts
$3K
Net Calls
+$14K
Net Calls Change
+$8K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$82.6K
2
Charles Schwab
Charles Schwab
California
+$40.2K
3
V
Veritable
Delaware
+$34.9K
4
Millennium Management
Millennium Management
New York
+$33.8K
5
TRCT
Tower Research Capital (TRC)
New York
+$11.7K

Top Sellers

Rank Fund Capital Flow
1
EP
Eversept Partners
New York
-$154K
2
SFG
SVB Financial Group
Texas
-$36.6K
3
Two Sigma Investments
Two Sigma Investments
New York
-$10.9K
4
UBS Group
UBS Group
Switzerland
-$9.47K
5
Rockefeller Capital Management
Rockefeller Capital Management
New York
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$5.49M – – –
CAM
2
Cormorant Asset Management
Massachusetts
$2.87M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$1.6M – – –
WP
4
Woodline Partners
California
$1.22M – – –
Ensign Peak Advisors
5
Ensign Peak Advisors
Utah
$1.05M – – –
CM
6
CM Management
Florida
$554K – – –
IC
7
Ikarian Capital
Texas
$524K – – –
Geode Capital Management
8
Geode Capital Management
Massachusetts
$305K – – –
JE
9
JMAC Enterprises
Pennsylvania
$129K – – –
BlackRock
10
BlackRock
New York
$124K +$2.14K +798 +2%
ISL
11
Ingalls & Snyder LLC
New York
$120K – – –
State Street
12
State Street
Massachusetts
$105K – – –
Renaissance Technologies
13
Renaissance Technologies
New York
$76K +$6.7K +2,500 +8%
Citadel Advisors
14
Citadel Advisors
Florida
$72.7K +$82.6K +30,810 New
Northern Trust
15
Northern Trust
Illinois
$70.9K – – –
SFG
16
SVB Financial Group
Texas
$63.6K -$36.6K -13,671 -34%
Two Sigma Advisers
17
Two Sigma Advisers
New York
$59.2K -$1.34K -500 -2%
BFM
18
Boothbay Fund Management
New York
$52K – – –
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$42.4K – – –
Two Sigma Investments
20
Two Sigma Investments
New York
$41.5K -$10.9K -4,051 -19%
Mercer Global Advisors
21
Mercer Global Advisors
Colorado
$39K – – –
Charles Schwab
22
Charles Schwab
California
$35.4K +$40.2K +14,987 New
V
23
Veritable
Delaware
$30.7K +$34.9K +13,029 New
Millennium Management
24
Millennium Management
New York
$30K +$33.8K +12,605 New
TRCT
25
Tower Research Capital (TRC)
New York
$15K +$11.7K +4,353 +229%
1
2

ELDN Hedge Fund Activity: Q1 2023 in Review

30 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2023, worth a combined $14.7M — up 2.7% from $14.3M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ELDN positions and 5 closed out — a net gain of 2 holders — while 4 added to existing stakes and 4 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $82.6K. The largest seller was Eversept Partners, exiting entirely with an estimated $154K sold.

  • 30 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2023, up from 28 in Q4 2022.
  • Funds reported $14.7M of Eledon Pharmaceuticals stock for Q1 2023, up 2.7% quarter-over-quarter.
  • 7 funds opened new Eledon Pharmaceuticals positions in Q1 2023 and 5 closed out, a net change of +2 holders.
  • The largest Eledon Pharmaceuticals buyer in Q1 2023 was Citadel Advisors, an estimated $82.6K added.
  • The largest Eledon Pharmaceuticals seller in Q1 2023 was Eversept Partners, an estimated $154K sold.

Based on aggregated 13F filings for Q1 2023.